gwph-ex1081

Following the recommendation of the nomination committee, the Board of GW has appointed you as an independent, non-executive Director. I am writing to record the terms of your appointment as a non-executive Director of GW. These terms will take effect on 21 December 2017 and will continue until terminated by either party giving to the other not less than 3 months’ prior written notice or as provided for in paragraph 1 below.

By accepting this appointment, you agree that this letter is a contract for services and is not a contract of employment and you confirm that you are not subject to any restrictions which prevent you from holding office as a Director.

(a)

Your appointment as a non-executive Director of GW is subject to the Articles of Association of GW. You are required to retire and seek reelection by our shareholders at the next AGM, which is on 14 March 2018, and at any subsequent AGM as required by the Articles of Association or as the Board resolves. The Articles of Association require one third of the Directors to retire by rotation and seek re-election at each AGM, with each director being subject to re-election at intervals of not more than three years. Your appointment as a non-executive Director will automatically terminate without any entitlement to compensation if you:

(iii)

cease to be a director by reason of your vacating office pursuant to any provision of the Company’s Articles of Association.

(b)

The Company may terminate your appointment with immediate effect if you:

(i)

commit any act, whether or not in the course of your duties for the Company, which tends to bring you or the Company or Group into disrepute;

(iii)

commit any serious or repeated breach or non-observance of your obligations to the Company (which include an obligation not to breach your duties to the Company, whether statutory, fiduciary or common law);

(iv)

are declared bankrupt or have made an arrangement with, or for the benefit of, your creditors;

(v)

are convicted of any arrestable criminal offence (other than an offence under road traffic legislation in the UK or elsewhere for which a fine or non-custodial penalty is imposed);

(vii)

are unavailable to perform your duties under your appointment for 6 months consecutively or in aggregate in any period of one year.

(c)

During any period of notice in accordance with this agreement, the Company may at its absolute discretion ask you not to attend any Board or General meetings or to perform any other services on its behalf.

(d)

Non-executive directors on the GW Board are typically expected to serve two three-year terms but you may be invited by the Company to serve for an additional period on the Board. Any term renewal after your first three-year term is subject to Board review and re-election at the subsequent AGM. Notwithstanding any mutual expectation, there is no right to renomination by the Board, either annually or after any three-year period.

(e)

Upon the ending of your appointment for any reason, you will resign at the request of the Company, without any claim for compensation (other than for accrued and unpaid fees due under this letter), from all directorships and other offices held by you in the Company and any other member of the Group and from all trusteeships held by you of any pension scheme or other trusts established by any member of the Group. Should you fail to do so, you irrevocably appoint any member of the Board as your attorney in your name and on your behalf to sign any documents and take such other steps as are necessary to give effect to those resignations.

(f)

If matters arise which cause you concern about your role, you should discuss these matters with the Chairman of the Company. If you have any concerns which cannot be resolved, and you choose to resign for that, or any other, reason, you should provide an appropriate written statement to the Chairman of the Company for circulation to the Board.

(a)

You will be expected to devote such time as is necessary for the proper performance of your duties. You are expected to attend GW Board Meetings and General Meetings of the shareholders of GW as and when they are held. In connection with

attendance at the meetings, you will exercise such functions that are specifically delegated to you from time to time by the Board.

(b)

You will also likely be required to sit on at least one sub sub-committee of the Board.

(c)

We expect this role to involve attendance at least five GW Board meetings, the GW Annual General Meeting (usually held on the same day as a Board meeting) and, Audit Committee meetings (typically scheduled to occur on Board meeting dates). Unless urgent and unavoidable circumstances prevent you from doing so, it is expected that you will attend these meetings, most of which will be held in the UK. One Board meeting per year is likely to be in the U.S.

(d)

Additional time may be required, on an ad-hoc basis, to attend meetings to deal with certain GW Board and sub-committee matters as they arise. The nature of the role makes it impossible to be specific about the maximum time commitment, and there is always the possibility of additional time commitment in respect of preparation time and ad hoc matters which may arise from time to time, and particularly when the Company is undergoing a period of increased activity. At certain times, it may be necessary to convene additional GW Board, committee or shareholder meetings.

(e)

In accepting this role you confirm that you have sufficient time available to commit to the proper performance of this role. Prior to acceptance of the role you will be required to provide to the Company Secretary details of your other Board appointments and significant commitments with a broad indication of the time involved and will be required to update the Company Secretary from time to time of any changes to these commitments.

(a)

You shall be paid an annual fee of $60,000 gross (current at the date of this letter). This fee covers all duties, excluding service on any subcommittee of the Board. If you are required to sit on a sub-committee committee, you will be paid an additional annual fee. This fee will vary depending upon the sub-committee on which you sit, as follows:


Sub-committee	Annual Fee
Audit Committee	$10,000
Nominations Committee	$5,000
Remuneration Committee	$7,500

Additional fees will also be payable in future if you are asked to become a member of an additional Board sub-committee or if you are asked to take up the role of Chair of any sub-committee. Your fees shall be paid in equal instalments monthly in arrear after deduction of any taxes and other amounts that are required by law.

(b)

Your fees will be reviewed from time to time by the GW Board. It is our current practice to review these fees at the end of each calendar year although such review does not imply nor guarantee any increase.

(c)

You will not be entitled to participate in any Group pension scheme or to receive any other benefits offered by the Company.

(d)

You will be eligible to participate in the GW Pharmaceuticals Long Term Incentive Plan. Grants of equity based incentives under the terms of this scheme are made at the discretion of the Board, usually on an annual basis.

(e)

You will be reimbursed for all reasonable out-of-pocket expenses properly incurred by you on Company business, including costs associated with you attending UK Board, Committee and General Meetings so long as those costs are in accordance with the GW travel policy (a copy of which will be provided to you on request). Reimbursement would include the reasonable cost of obtaining legal advice, if circumstances should arise where it was necessary for you to seek such advice separately, about your responsibilities as a non-executive director of the Company although you should initially raise any such concerns with the Chairman of the Company. This advice should be obtained, and reimbursement will only be made, in accordance with any formal procedure for directors to take independent professional advice adopted from time to time by the Company and a copy of the current version will be supplied to you. Claims for reimbursement should be accompanied by evidence of expenditure.

The Company will, at its expense, provide you with director’s and officer’s liability insurance, subject to the provisions governing such insurance and on such terms as the Board may from time to time decide (including but not limited to terms relating to the level of cover, deductibles, caps, exclusions and aggregate limits) and subject to the obtaining of insurance at reasonable rates of premium. No undertaking is given regarding the continuation of this insurance, other than that you will be covered for as long as it remains in place for the directors of the Company.

The Board as a whole is collectively responsible for the success of the Company. The Board’s role is to provide entrepreneurial leadership of the Company within a framework of prudent and effective controls which enable risk to be assessed and managed, set the Company’s strategic aims, ensure that the necessary financial and human resources are in place for the Company to meet its objectives, and review management performance; and ensure that its obligations to its shareholders and others are understood and met.

(a)

You will be expected to perform your duties, whether statutory, fiduciary or common-law, faithfully, efficiently and diligently to a standard commensurate with both the functions of your role and your knowledge, skills and experience.

(b)

You will exercise your powers in your role as a non-executive director having regard to relevant obligations under prevailing law and regulation, including the Companies Act 2006. You are also required to comply with the requirements of Nasdaq. You will be advised by the Company Secretary where these differ from requirements in the UK.

(c)

You will have particular regard to the general duties of directors as set out in Part 10, Chapter 2 of the Companies Act 2006, including the duty to promote the success of the company:

“A director of a company must act in the way he considers, in good faith, would be most likely to promote the success of the company for the benefit of its members as a whole, and in doing so have regard (amongst other matters) to -

(c)

the need to foster the company’s business relationships with suppliers, customers and others,

(d)

the impact of the company’s operations on the community and the environment,

(e)

the desirability of the company maintaining a reputation for high standards of business conduct, and

•

scrutinise the performance of management in meeting agreed goals and objectives and monitor the reporting of performance;

•

satisfy yourself on the integrity of financial information and that financial controls and systems of risk management are robust and defensible;

•

determine appropriate levels of remuneration of executive directors and have a prime role in appointing and, where necessary, removing executive directors, and in succession planning;

•

uphold high standards of integrity and probity and support me and the other directors in instilling the appropriate culture, values and behaviours in the boardroom and beyond;

•

insist on receiving high-quality information sufficiently in advance of board meetings; and

•

take into account the views of shareholders and other stakeholders where appropriate.

(e)

You will be required to exercise relevant powers under, and abide by, GW’s Articles of Association.

(f)

You will be required to exercise your powers as a director in accordance with GW’s policies and procedures.

(g)

You will disclose any direct or indirect interest which you may have in any matter being considered at a board meeting or committee meeting and, save as permitted under the Articles of Association, you will not vote on any resolution of the Board, or of one of its committees, on any matter where you have any direct or indirect interest.

(h)

You will immediately report to the Chairman your own wrongdoing or the wrongdoing or proposed wrongdoing of any employee or director of which you become aware.

(i)

Unless specifically authorised to do so by the Board, you will not enter into any legal or other commitment or contract on behalf of the Company.

During your appointment you may not, without the prior approval of the Board, accept a directorship of a company or provide your services to anyone who is a competitor of the Group. The Board’s agreement will not be given if such appointment or involvement would conflict with or is likely to interfere with this appointment. It is the parties understanding that the definition of a competitor shall be restricted to a project, business or activity, directly or indirectly, involving cannabinoid research, or the research or treatment of epilepsy. Please let the Company Secretary have a list of your current commitments for our records and keep him updated in that respect.

You should not, during your appointment (except in the proper performance of your duties and then only to those who need to know such information) or after it has ceased (except as required by law), disclose to any person, company or other organisation or use otherwise than for the benefit of the Group any confidential information or trade secrets concerning its business. This includes but is not limited to:

(a)

corporate and marketing strategy, acquisition and investment proposals, business development and plans, maturing business opportunities, sales reports and research results;

(b)

business contacts, lists of customers and suppliers and details of contracts with customers and suppliers and their current or future requirements;

(c)

budgets, financial plans and management accounts, trading statements and other financial reports and information;

(e)

any document marked “confidential” and any information which by its nature is commercially sensitive.

(a)

You are expected to comply with the Company’s Articles of Association, the City Code on Takeovers and Mergers, applicable stock exchange rules and regulations and the Company’s relevant internal codes and policies. In particular during your appointment you will comply, and will procure, so far as you are able, that your spouse or Civil Partner and dependent children (if any) or any trust in which you or your spouse or Civil Partner may be concerned or interested as trustee or beneficiary, comply with any code of conduct relating to securities transactions by directors and specified employees adopted by the Company from time to time.

(b)

You will promptly give the Company such information as the Company or any member of the Group may require to enable it to comply with its legal and regulatory obligations whether to any securities or investment exchange or regulatory or governmental body to which any member of the Group is, from time to time, subject or howsoever arising.

(c)

You will promptly give the Company such information, records and support as the Company or any member of the Group may require to enable it to prepare for, or respond to, any proceedings, inquiries or investigations into its activities by a regulatory or governmental authority. This requirement will survive termination or expiration of your appointment.

When your appointment ends, you should, unless otherwise agreed in writing, immediately return all documents and other property belonging to any member of the Group and which may be in your possession or under your control. No copies (including electronic copies) should be retained by you or by anyone on your behalf.

By signing this letter you consent to the Company holding and processing information about you for legal, personnel, administrative and management purposes and in particular to the processing of any sensitive personal data (as defined in applicable UK Data Protection laws from time to time) including, as and when appropriate:

(i)

information about your physical or mental health or condition in order to monitor sick leave and take decisions as to your fitness to perform your duties;

(ii)

information about you that may be relevant to ensuring equality of opportunity and treatment in line with the Company’s equal opportunities policy and in compliance with equal opportunities legislation; and

(iii)

information relating to any criminal proceedings in which you have been involved, for insurance purposes and in order to comply with legal requirements and obligations to third parties.

You consent to the transfer of such personal information to any member of the Group (or a company appointed by them for such purposes), whether or not outside the European Economic Area, for administration purposes and other purposes in connection with your appointment, where it is necessary or desirable for the Company to do so.

In consideration for the fees payable to you under this letter, you agree you will not (except with prior written consent of the GW Board) directly or indirectly do or attempt to, for the period of 12 months immediately after the termination of your office, to any material extent, undertake, carry on or be employed, engaged or interested in any capacity in the supply or proposed supply of Competitive Services within the Territory. For the purposes of this paragraph, “Competitive Services” means any business connected to the marketing, sales or distribution, or development or proposed development of pharmaceuticals from cannabinoids which is competitive with the Company’s or GW, or GW Pharma’s businesses; and “Territory” means United States of America, England, Wales, Scotland, Northern Ireland and any other country, or, in the United States, any state, which the Company or any member of the Group is operating or planning to operate a competitive business at the end of your appointment. This requirement will survive termination or expiration of your appointment.

The Contracts (Rights of Third Parties) Act 1999 shall not apply to this letter. No person other than you and the Company shall have any rights under this letter and the terms of this letter shall not be enforceable by any person other than you and the Company.

the “Board” shall mean the board of directors of the Company as constituted from time to time;

“Civil Partner” means a civil partner as defined by the Civil Partnership Act 2004; and

the “Group” means any of the following from time to time: the Company, its subsidiaries and subsidiary undertakings and any holding company or parent undertaking of the Company and all other subsidiaries and subsidiary undertakings of any holding company or parent undertaking of the Company, where “holding company”, “parent undertaking”, “subsidiary” and “subsidiary undertaking” have the meanings given to them in the Companies Act 2006.

(b)

This letter will be construed in accordance with English law and you and the Company irrevocably submit to the exclusive jurisdiction of the English Courts to settle any dispute which may arise in connection with this letter.

(c)

This letter constitutes the entire terms and conditions of your appointment. No variation or addition to this letter and no waiver of any provision of it will be valid unless in writing and signed by or on behalf of both parties.

I would ask you to countersign the enclosed copy of this letter to confirm the basis of your appointment with the Company and to show acceptance of the terms of this letter by executing it as a deed.


730616619.1	1


730616619.1	2


730616619.1	3


730616619.1	4